Latest news
Sanofi halt spotlights OX40L as Korea’s IMBiologics bets on bispecifics - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 04 Aug 2026 21:01:00 GMTSanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study - TipRanksTipRanks · Wed, 29 Jul 2026 07:00:00 GMTDual-Targeting Library: Designing Novel Bispecific Therapeutics - SanofiSanofi · Tue, 28 Jul 2026 07:00:00 GMT